Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Lowered by Leede Financial

Oncolytics Biotech (NASDAQ:ONCY) was downgraded by stock analysts at Leede Financial from a “strong-buy” rating to a “moderate buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Oncolytics Biotech in a research note on Thursday.

Oncolytics Biotech Stock Down 3.0 %

ONCY stock traded down $0.03 during trading on Wednesday, hitting $0.98. The company had a trading volume of 245,358 shares, compared to its average volume of 328,224. The firm has a market capitalization of $75.53 million, a P/E ratio of -3.63 and a beta of 1.69. Oncolytics Biotech has a 52-week low of $0.84 and a 52-week high of $1.75. The company has a 50 day simple moving average of $1.09 and a 200-day simple moving average of $1.06.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC acquired a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech at the end of the most recent quarter. 6.82% of the stock is currently owned by institutional investors and hedge funds.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.